
Qureight, a biotech company based in Cambridge, UK, recently secured $8.5M in Series A funding. This funding round was led by Hargreave Hale AIM VCT and included participation from XTX Ventures, Guinness Ventures, Playfair Capital, Meltwind, Ascension Life Fund, and Cambridge Angels. The company plans to use this injection of capital to expand its operations and ramp up its research and development efforts in the near future.
Dr.
Muhunthan Thillai, the CEO of Qureight, leads the company in its mission to accelerate the development of clinical trials through innovative data curation and AI-powered decision-making processes. By leveraging a sophisticated platform that collects and analyzes data using advanced AI models, Qureight aims to help researchers make more informed decisions at critical junctures in the clinical trial process. With the global clinical trials market poised to surpass $92bn by 2030, the company is well-positioned to make a significant impact in this rapidly expanding industry.
Already, Qureight has formed partnerships with major pharmaceutical companies such as AstraZeneca and Vicore Pharma, in addition to signing research and development contracts with five NHS England trusts. Through these collaborations and its cutting-edge technology, the company is poised to revolutionize the drug development process and bring new treatments to patients in need. With the support of its investors and the leadership of Dr. Thillai, Qureight is poised for continued success and growth in the coming years.
| Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|
![]() Hargreave Hale AIM VCT | 1 investment investment | more info | |||
![]() XTX Ventures | 13 investments investments | 1 contact contact | |||
![]() Guiness Asset Management | 4 investments investments | 1 contact contact | |||
![]() Playfair Capital | 12 investments investments | 4 contacts contacts | |||
![]() Meltwind | 4 investments investments | 1 contact contact |
Click here for a full list of 7,526+ startup investors in the UK